Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection

Autor: Teresa M. Hesley, Mauricio Hernández-Ávila, Luisa L. Villa, Daron G. Ferris, Annemarie R. Thornton, Nubia Muñoz, Margaret James, Laura A. Koutsky, Radha Railkar, Robert J. Kurman, Steinar Thoresen, Carlos Sattler, Gonzalo Perez, Evan R. Myers, Hseon Tay Eng, Eliav Barr, Susanne K. Kjaer, Mark T. Esser, Kevin A. Ault, Patricia J. Garcia, Kristjan Sigurdsson, Darron R. Brown, Ole Eric Iversen, Janine T. Bryan, Scott Vuocolo, Sven Eric Olsson, Joakim Dillner, Micki Nelson, Slawomir Majewski, Matti Lehtinen, Jorma Paavonen, John W. Boslego, F. Xavier Bosch, Frank J. Taddeo
Rok vydání: 2006
Předmět:
Adult
medicine.medical_specialty
Adolescent
Population
Uterine Cervical Neoplasms
Enzyme-Linked Immunosorbent Assay
Disease
Cervical intraepithelial neoplasia
Antibodies
Viral
Injections
Intramuscular
Polymerase Chain Reaction
03 medical and health sciences
0302 clinical medicine
Double-Blind Method
Internal medicine
medicine
Immunology and Allergy
Humans
030212 general & internal medicine
Papillomavirus Vaccines
Prospective Studies
Human papillomavirus
education
Papillomaviridae
education.field_of_study
Hpv types
business.industry
Papillomavirus Infections
HPV infection
virus diseases
Sexually Transmitted Diseases
Viral
medicine.disease
Uterine Cervical Dysplasia
female genital diseases and pregnancy complications
Confidence interval
3. Good health
Vaccination
Infectious Diseases
Treatment Outcome
030220 oncology & carcinogenesis
DNA
Viral
Female
business
Zdroj: The Journal of infectious diseases. 196(10)
ISSN: 0022-1899
Popis: Background. A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle (VLP) vaccine has been shown to be 95%-100% effective in preventing cervical and genital disease related to HPV-6,-11,-16, and-18 in 16-26-year-old women naive for HPV vaccine types. Because most women in the general population are sexually active, some will have already been infected with >= 1 HPV vaccine types at the time vaccination is offered. Here, we assessed whether such infected women are protected against disease caused by the remaining HPV vaccine types. Methods. Two randomized, placebo-controlled trials of the quadrivalent (types 6, 11, 16, and 18) HPV vaccine enrolled 17,622 women without consideration of baseline HPV status. Among women infected with 1-3 HPV vaccine types at enrollment, efficacy against genital disease related to the HPV vaccine type or types for which subjects were naive was assessed. Results. Vaccination was 100% effective (95% confidence interval [CI], 79%-100%) in preventing incident cervical intraepithelial neoplasia 2 or 3 or cervical adenocarcinoma in situ caused by the HPV type or types for which the women were negative at enrollment. Efficacy for preventing vulvar or vaginal HPV-related lesions was 94% (95% CI, 81%-99%). Conclusions. Among women positive for 1-3 HPV vaccine types before vaccination, the quadrivalent HPV vaccine protected against neoplasia caused by the remaining types. These results support vaccination of the general population without prescreening. (Less)
Databáze: OpenAIRE
Externí odkaz: